{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:54:30Z","timestamp":1767664470686},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Anaesthesist"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1007\/s00101-005-0962-7","type":"journal-article","created":{"date-parts":[[2006,1,2]],"date-time":"2006-01-02T10:52:42Z","timestamp":1136199162000},"page":"443-450","source":"Crossref","is-referenced-by-count":11,"title":["Argatroban"],"prefix":"10.1007","volume":"55","author":[{"given":"S.","family":"Kleinschmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pindur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"962_CR1","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1345\/aph.1D010","volume":"37","author":"Dager","year":"2003","unstructured":"Dager WE, White RH (2003) Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD. Ann Pharmacother 37:1232\u20131236","journal-title":"Ann Pharmacother"},{"key":"962_CR2","first-page":"218","volume":"44","author":"Deutsche","year":"2003","unstructured":"Deutsche Gesellschaft f\u00fcr An\u00e4sthesiologie und Intensivmedizin (2003) R\u00fcckenmarknahe Regionalan\u00e4sthesien und Thromboembolieprophylaxe\/antithrombotische Medikation. Anaesthesiol Intensivmed 44:218\u2013230","journal-title":"Anaesthesiol Intensivmed"},{"key":"962_CR3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1460-9592.2005.01417.x","volume":"15","author":"Dyke","year":"2005","unstructured":"Dyke P, Russo P, Mureebe L et al. (2005) Argatroban for anticoagulation during cardiopulmonary bypass in an infant. Pediatr Anesth 15:328\u2013333","journal-title":"Pediatr Anesth"},{"key":"962_CR4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.athoracsur.2004.04.037","volume":"78","author":"Gasparovic","year":"2004","unstructured":"Gasparovic H, Nathan N, Fitzgerald D et al. (2004) Severe argatroban-induced coagulopathy in a patient with a history of heparin-induced thrombocytopenia. Ann Thorac Surg 78:89\u201391","journal-title":"Ann Thorac Surg"},{"key":"962_CR5","unstructured":"Greinacher A, Lubenow N, Hinz P, Ekkernkamp A (2003) Heparininduzierte Thrombozytopenie. Dtsch Arztebl 100 (34\/35):A2220\u2013A2229"},{"key":"962_CR6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11239-005-0942-4","volume":"19","author":"Harenberg","year":"2005","unstructured":"Harenberg J, J\u00f6rg I, Tivadar F et al. (2005) Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban. J Thromb Thrombolysis 19:65\u201369","journal-title":"J Thromb Thrombolysis"},{"key":"962_CR7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11239-004-0171-2","volume":"18","author":"Jang","year":"2004","unstructured":"Jang I, Lewis BE, Matthai W et al. (2004) Argatroban anticoagulation in conjunction with glycoprotein IIb\/IIIa Inhibition in patients undergoing percutaneous coronary intervention: An open-label, nonrandomized pilot study. J Thromb Thrombolysis 18:31\u201337","journal-title":"J Thromb Thrombolysis"},{"key":"962_CR8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1015368126304","volume":"13","author":"Kathiresan","year":"2002","unstructured":"Kathiresan S, Shiomura J, Jang IK (2002) Argatroban. J Thromb Thrombolysis 13:41\u201347","journal-title":"J Thromb Thrombolysis"},{"key":"962_CR9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s001010050785","volume":"48","author":"Kleinschmidt","year":"1999","unstructured":"Kleinschmidt S, Seyfert UT (1999) Die Heparin-induzierte Thrombozytopenie. Bedeutung f\u00fcr An\u00e4sthesie und Intensivmedizin. Anaesthesist 48:771\u2013785","journal-title":"Anaesthesist"},{"key":"962_CR10","unstructured":"Lewis BE, Hursting M (2001) Argatroban in heparin-induced thrombocytopenia. In: Warkentin T, Greinacher A (eds) Heparin-induced thrombocytopenia. Dekker, New York, pp\u00a0381\u2013407"},{"key":"962_CR11","doi-asserted-by":"crossref","unstructured":"Lewis BE, Walenga JM (2002) Argatroban in HIT type II and acute coronary syndrome. Pathophysiol Haemost Thromb 32 [Suppl 3]:46\u201355","DOI":"10.1159\/000069109"},{"key":"962_CR12","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","volume":"103","author":"Lewis","year":"2001","unstructured":"Lewis BE, Wallis DE, Berkowitz SE et al. (2001) Argatroban anticoagulation therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838\u20131843","journal-title":"Circulation"},{"key":"962_CR13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ccd.10276","volume":"57","author":"Lewis","year":"2002","unstructured":"Lewis BE, Matthai WH, Cohen M et al. (2002) Argatroban anticoagulation during percutaneous intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Intervent 57:177\u2013184","journal-title":"Catheter Cardiovasc Intervent"},{"key":"962_CR14","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","volume":"163","author":"Lewis","year":"2003","unstructured":"Lewis BE, Wallis D, Leya F et al. (2003) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Int Med 163:1849\u20131856","journal-title":"Arch Int Med"},{"key":"962_CR15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.thromres.2004.11.006","volume":"116","author":"Matthai","year":"2005","unstructured":"Matthai WH, Hursting MJ, Lewis BE et al. (2005) Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 116:121\u2013126","journal-title":"Thromb Res"},{"key":"962_CR16","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1523-1755.2004.66022.x","volume":"66","author":"Murray","year":"2004","unstructured":"Murray PT, Reddy BV, Grossman EJ et al. (2004) A prospective comparison of three argatroban treatment regimens during hemodialysis in end stage renal disease. Kidney Int 66:2446\u20132453","journal-title":"Kidney Int"},{"key":"962_CR17","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMra044440","volume":"353","author":"Nisso","year":"2005","unstructured":"Nisso M de, Middeldorp S, B\u00fcller H (2005) Direct thrombin inhibitors. N Engl J Med 353:1028\u20131040","journal-title":"N Engl J Med"},{"key":"962_CR18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.1525-139X.2003.03014.x","volume":"16","author":"O\u2019Shea","year":"2003","unstructured":"O\u2019Shea S, Ortel T, Kovalik EC (2003) Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial 16:61\u201367","journal-title":"Semin Dial"},{"key":"962_CR19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/bja\/aeg063","volume":"90","author":"Parvinkumar","year":"2003","unstructured":"Parvinkumar E, Webster NR (2003) HIT\/HITT and alternative anticoagulation: current concepts. Br J Anesth 90:676\u2013685","journal-title":"Br J Anesth"},{"key":"962_CR20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1055\/s-0038-1649820","volume":"74","author":"Sakamoto","year":"1995","unstructured":"Sakamoto S, Hirase T, Suzuki S et al. (1995) Inhibitory effect of argatroban on thrombin-antithrombin III complex after percutaneous transluminal coronary angioplasty. Thromb Haemost 74:801\u2013802","journal-title":"Thromb Haemost"},{"key":"962_CR21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199509213331203","volume":"333","author":"Serruys","year":"1995","unstructured":"Serruys PW, Herrmann JP, Simon R et al. (1995) A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 333:757\u2013763","journal-title":"N Engl J Med"},{"key":"962_CR22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/107602960501100403","volume":"11","author":"Smythe","year":"2005","unstructured":"Smythe MR, Stephens J, Koerber JM et al. (2005) A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost 11:371\u2013374","journal-title":"Clin Appl Thromb Hemost"},{"key":"962_CR23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","volume":"45","author":"Stangier","year":"2005","unstructured":"Stangier J, Eriksson BI, Dahl O et al. (2005) Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 45:555\u2013563","journal-title":"J Clin Pharmacol"},{"key":"962_CR24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","volume":"20","author":"Swan","year":"2000","unstructured":"Swan SK, Hursting MJ (2000) The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20:318\u2013329","journal-title":"Pharmacotherapy"},{"key":"962_CR25","doi-asserted-by":"crossref","unstructured":"Walenga J (2002) An overview of the direct thrombin inhibitor argatroban. Pathophysiol Haemost Thromb 32 [Suppl 3]:9\u201314","DOI":"10.1159\/000069103"},{"key":"962_CR26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1365-2141.2003.04334.x","volume":"121","author":"Warkentin","year":"2003","unstructured":"Warkentin T (2003) Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121:535\u2013555","journal-title":"Br J Haematol"},{"key":"962_CR27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1378\/chest.126.3_suppl.311S","volume":"126","author":"Warkentin","year":"2004","unstructured":"Warkentin T, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment and prevention: the seventh ACCP consensus conference on antithrombotic and thrombolytic therapy. Chest 126:311\u2013337","journal-title":"Chest"}],"container-title":["Der Anaesthesist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-005-0962-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00101-005-0962-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00101-005-0962-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T22:56:48Z","timestamp":1558565808000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00101-005-0962-7"}},"subtitle":["Pharmakologische Eigenschaften und an\u00e4sthesiologische Aspekte"],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["962"],"URL":"https:\/\/doi.org\/10.1007\/s00101-005-0962-7","relation":{},"ISSN":["0003-2417","1432-055X"],"issn-type":[{"value":"0003-2417","type":"print"},{"value":"1432-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}